Anta Gkelou

Anta is a Partner in the Sofinnova Capital Strategy. She joined us in 2017. Previously, Anta was an immunology scientist at Danone Nutricia, where she was involved in translational research and development of prebiotic and probiotic products for immune resilience.

Anta completed her PhD at the National Heart and Lung Institute of Imperial College in London in collaboration with Pfizer UK, where she studied the biology of oxidative stress-driven steroid insensitivity in COPD. She continued her post-doctoral studies at the National Institute of Health of France, INSERM, where she investigated the molecular and cellular mechanisms that regulate cardiomyocyte function post myocardial infarction at the European Hospital George Pompidou in Paris.